Nature, ISSN 0028-0836, 02/2015, Volume 518, Issue 7540, pp. 495 - 501
Pancreatic cancer remains one of the most lethal of malignancies and a major health burden. We performed whole-genome sequencing and copy number variation...
REARRANGEMENT | INSTABILITY | METAANALYSIS | RANDOMIZED-TRIALS | ADENOCARCINOMA | MULTIDISCIPLINARY SCIENCES | GENES | PATTERNS | CHROMOTHRIPSIS | GEMCITABINE | CHEMOTHERAPY | Genomics | Humans | DNA Repair - genetics | Carcinoma, Pancreatic Ductal - genetics | Pancreatic Neoplasms - drug therapy | Point Mutation - genetics | DNA Mutational Analysis | Genes, BRCA2 | Pancreatic Neoplasms - classification | Female | Adenocarcinoma - genetics | Genes, BRCA1 | Platinum - pharmacology | Genomic Instability - genetics | Genotype | Pancreatic Neoplasms - genetics | Mutation - genetics | Adenocarcinoma - drug therapy | Poly(ADP-ribose) Polymerase Inhibitors | Genome, Human - genetics | Xenograft Model Antitumor Assays | Carcinoma, Pancreatic Ductal - drug therapy | Animals | Genetic Markers - genetics | Mice | Copy number variations | Pancreatic cancer | Physiological aspects | Development and progression | Genetic aspects | Research | Tumor proteins | Risk factors | Genes | DNA damage | Clinical trials | Genomes | Cancer therapies | Patients | Biomarkers | Mutation | Chromosomes | Deoxyribonucleic acid--DNA | Tumors
REARRANGEMENT | INSTABILITY | METAANALYSIS | RANDOMIZED-TRIALS | ADENOCARCINOMA | MULTIDISCIPLINARY SCIENCES | GENES | PATTERNS | CHROMOTHRIPSIS | GEMCITABINE | CHEMOTHERAPY | Genomics | Humans | DNA Repair - genetics | Carcinoma, Pancreatic Ductal - genetics | Pancreatic Neoplasms - drug therapy | Point Mutation - genetics | DNA Mutational Analysis | Genes, BRCA2 | Pancreatic Neoplasms - classification | Female | Adenocarcinoma - genetics | Genes, BRCA1 | Platinum - pharmacology | Genomic Instability - genetics | Genotype | Pancreatic Neoplasms - genetics | Mutation - genetics | Adenocarcinoma - drug therapy | Poly(ADP-ribose) Polymerase Inhibitors | Genome, Human - genetics | Xenograft Model Antitumor Assays | Carcinoma, Pancreatic Ductal - drug therapy | Animals | Genetic Markers - genetics | Mice | Copy number variations | Pancreatic cancer | Physiological aspects | Development and progression | Genetic aspects | Research | Tumor proteins | Risk factors | Genes | DNA damage | Clinical trials | Genomes | Cancer therapies | Patients | Biomarkers | Mutation | Chromosomes | Deoxyribonucleic acid--DNA | Tumors
Journal Article
Gut, ISSN 0017-5749, 12/2018, Volume 67, Issue 12, pp. 2142 - 2155
ObjectiveExtensive molecular heterogeneity of pancreatic ductal adenocarcinoma (PDA), few effective therapies and high mortality make this disease a prime...
molecular mechanisms | pancreatic cancer | cell cycle | extracellular matrix | KINASE 4/6 INHIBITOR | BREAST-CANCER | SURVIVAL | PALBOCICLIB | THERAPY | DUCTAL ADENOCARCINOMA | NAB-PACLITAXEL | FULVESTRANT | CELL-CYCLE | GASTROENTEROLOGY & HEPATOLOGY | GEMCITABINE | Phosphorylation | Pancreatic Neoplasms - metabolism | Prognosis | Humans | Pancreatic Neoplasms - pathology | Retinoblastoma Protein - metabolism | Carcinoma, Pancreatic Ductal - metabolism | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Carcinoma, Pancreatic Ductal - pathology | Pancreatic Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Carcinoma, Pancreatic Ductal - drug therapy | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Biomarkers, Tumor - metabolism | Mice, Inbred BALB C | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Molecular Targeted Therapy - methods | Disease Models, Animal | Pyridines - therapeutic use | Cell proliferation | Adenocarcinoma | Animal models | Genomes | Shear stresses | Metastasis | Kinases | Cancer therapies | Phase transitions | Cyclin-dependent kinase 4 | Metastases | Proteins | Cyclin-dependent kinase | Signal transduction | Cell cycle | Extracellular matrix | Cyclin D | Cyclin-dependent kinases | Retinoblastoma protein | Breast cancer | Patients | Chemotherapy | Molecular modelling | Pancreatic cancer | Biomarkers | Genetic engineering | Clinical medicine | Mutation | Retinoblastoma | Apoptosis | Tumors | 2312 | Pancreas | 1506
molecular mechanisms | pancreatic cancer | cell cycle | extracellular matrix | KINASE 4/6 INHIBITOR | BREAST-CANCER | SURVIVAL | PALBOCICLIB | THERAPY | DUCTAL ADENOCARCINOMA | NAB-PACLITAXEL | FULVESTRANT | CELL-CYCLE | GASTROENTEROLOGY & HEPATOLOGY | GEMCITABINE | Phosphorylation | Pancreatic Neoplasms - metabolism | Prognosis | Humans | Pancreatic Neoplasms - pathology | Retinoblastoma Protein - metabolism | Carcinoma, Pancreatic Ductal - metabolism | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Carcinoma, Pancreatic Ductal - pathology | Pancreatic Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Carcinoma, Pancreatic Ductal - drug therapy | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Biomarkers, Tumor - metabolism | Mice, Inbred BALB C | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Molecular Targeted Therapy - methods | Disease Models, Animal | Pyridines - therapeutic use | Cell proliferation | Adenocarcinoma | Animal models | Genomes | Shear stresses | Metastasis | Kinases | Cancer therapies | Phase transitions | Cyclin-dependent kinase 4 | Metastases | Proteins | Cyclin-dependent kinase | Signal transduction | Cell cycle | Extracellular matrix | Cyclin D | Cyclin-dependent kinases | Retinoblastoma protein | Breast cancer | Patients | Chemotherapy | Molecular modelling | Pancreatic cancer | Biomarkers | Genetic engineering | Clinical medicine | Mutation | Retinoblastoma | Apoptosis | Tumors | 2312 | Pancreas | 1506
Journal Article
NATURE COMMUNICATIONS, ISSN 2041-1723, 08/2019, Volume 10, Issue 1, pp. 3637 - 22
Heterogeneous subtypes of cancer-associated fibroblasts (CAFs) coexist within pancreatic cancer tissues and can both promote and restrain disease progression....
ACTIVATION | INVASION | DUCTAL ADENOCARCINOMA | IMMUNOTHERAPY | MULTIDISCIPLINARY SCIENCES | MUTANT P53 | MUTATIONAL LANDSCAPE | TUMOR-CELLS | STROMA | MOUSE MODELS | FIBROBLASTS | Chemotherapy | p53 Protein | Pancreatic cancer | Perlecan | Stroma | Fibroblasts | Metastasis | Cancer | Metastases
ACTIVATION | INVASION | DUCTAL ADENOCARCINOMA | IMMUNOTHERAPY | MULTIDISCIPLINARY SCIENCES | MUTANT P53 | MUTATIONAL LANDSCAPE | TUMOR-CELLS | STROMA | MOUSE MODELS | FIBROBLASTS | Chemotherapy | p53 Protein | Pancreatic cancer | Perlecan | Stroma | Fibroblasts | Metastasis | Cancer | Metastases
Journal Article
Rodriguesia, ISSN 0370-6583, 10/2015, Volume 66, Issue 4, pp. 1085 - 1113
Abstract An updated inventory of Brazilian seed plants is presented and offers important insights into the country's biodiversity. This work started in 2010,...
Biomes | Life-forms | Endemism | Angiosperms | Gymnosperms | life-forms | endemism | biomes
Biomes | Life-forms | Endemism | Angiosperms | Gymnosperms | life-forms | endemism | biomes
Journal Article
5.
Full Text
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Nature, ISSN 0028-0836, 11/2017, Volume 551, Issue 7681, pp. S12 - S16
Pancreatic ductal adenocarcinoma is a lethal cancer with fewer than 7% of patients surviving past 5 years. T-cell immunity has been linked to the exceptional...
CELLS | MUC16 | LANDSCAPE | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | DYNAMICS | HUMAN-MELANOMA | MICE | TUMORS | ANTIGEN | CA-125 Antigen - immunology | Cancer Survivors | Cross Reactions - genetics | Prognosis | CA-125 Antigen - genetics | Humans | Computer Simulation | Immunotherapy | Adenocarcinoma - genetics | Bacterial Proteins - immunology | T-Lymphocytes, Cytotoxic - immunology | Antigens, Neoplasm - genetics | Pancreatic Neoplasms - blood | Antigens, Neoplasm - immunology | Membrane Proteins - genetics | Adenocarcinoma - blood | Adenocarcinoma - immunology | Bacterial Proteins - genetics | Membrane Proteins - immunology | Pancreatic Neoplasms - genetics | Cross Reactions - immunology | Whole Exome Sequencing | Bacterial Proteins - blood | Pancreatic Neoplasms - immunology | Survival Analysis | T-Lymphocytes, Cytotoxic - cytology | Physiological aspects | Antigens | Health aspects | Pancreatic cancer | Adenocarcinoma | Transcription | Peptides | CD8 antigen | Homology | Lymphocytes T | Genomes | Immunity | Metastases | Cell activation | Microorganisms | Lymphocytes | Bioindicators | Medical research | Cell survival | T cell receptors | Epitopes | Biophysics | Patients | Studies | Chemotherapy | Infectious diseases | Immunogenicity | Biomarkers | Tumors | Cancer
CELLS | MUC16 | LANDSCAPE | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | DYNAMICS | HUMAN-MELANOMA | MICE | TUMORS | ANTIGEN | CA-125 Antigen - immunology | Cancer Survivors | Cross Reactions - genetics | Prognosis | CA-125 Antigen - genetics | Humans | Computer Simulation | Immunotherapy | Adenocarcinoma - genetics | Bacterial Proteins - immunology | T-Lymphocytes, Cytotoxic - immunology | Antigens, Neoplasm - genetics | Pancreatic Neoplasms - blood | Antigens, Neoplasm - immunology | Membrane Proteins - genetics | Adenocarcinoma - blood | Adenocarcinoma - immunology | Bacterial Proteins - genetics | Membrane Proteins - immunology | Pancreatic Neoplasms - genetics | Cross Reactions - immunology | Whole Exome Sequencing | Bacterial Proteins - blood | Pancreatic Neoplasms - immunology | Survival Analysis | T-Lymphocytes, Cytotoxic - cytology | Physiological aspects | Antigens | Health aspects | Pancreatic cancer | Adenocarcinoma | Transcription | Peptides | CD8 antigen | Homology | Lymphocytes T | Genomes | Immunity | Metastases | Cell activation | Microorganisms | Lymphocytes | Bioindicators | Medical research | Cell survival | T cell receptors | Epitopes | Biophysics | Patients | Studies | Chemotherapy | Infectious diseases | Immunogenicity | Biomarkers | Tumors | Cancer
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2015, Volume 10, Issue 12, p. e0144203
To investigate time-dependent predictors of institutionalization in old age using a longitudinal approach. In a representative survey of the German general...
Hearing Loss - diagnosis | Depression - physiopathology | Hearing Loss - physiopathology | Humans | Personality Assessment | Probability | Dementia - diagnosis | Dementia - physiopathology | Logistic Models | Male | Activities of Daily Living | Depression - diagnosis | Homes for the Aged - statistics & numerical data | Mobility Limitation | Aged, 80 and over | Marital Status - statistics & numerical data | Female | Aged | Longitudinal Studies | Germany | Nursing Homes - statistics & numerical data | Institutionalization - statistics & numerical data | Elderly people | Health services | Institutionalization | Mental health | Mobility | Long term health care | Mental depression | Ethics | Health economics | Older people | Dementia disorders | Aging | Occupational health | Medical statistics | Age | Public health | Nursing homes | Stability | Data structures | Patients | Hearing loss | Medicine | Nursing | Womens health | Blindness | Alzheimers disease | Econometrics | Psychiatry | Elderly | Geriatrics | Dementia
Hearing Loss - diagnosis | Depression - physiopathology | Hearing Loss - physiopathology | Humans | Personality Assessment | Probability | Dementia - diagnosis | Dementia - physiopathology | Logistic Models | Male | Activities of Daily Living | Depression - diagnosis | Homes for the Aged - statistics & numerical data | Mobility Limitation | Aged, 80 and over | Marital Status - statistics & numerical data | Female | Aged | Longitudinal Studies | Germany | Nursing Homes - statistics & numerical data | Institutionalization - statistics & numerical data | Elderly people | Health services | Institutionalization | Mental health | Mobility | Long term health care | Mental depression | Ethics | Health economics | Older people | Dementia disorders | Aging | Occupational health | Medical statistics | Age | Public health | Nursing homes | Stability | Data structures | Patients | Hearing loss | Medicine | Nursing | Womens health | Blindness | Alzheimers disease | Econometrics | Psychiatry | Elderly | Geriatrics | Dementia
Journal Article
Modern Pathology, ISSN 0893-3952, 09/2019
Journal Article
Science Translational Medicine, ISSN 1946-6234, 04/2017, Volume 9, Issue 384, pp. eaai8504 - eaai8504
The emerging standard of care for patients with inoperable pancreatic cancer is a combination of cytotoxic drugs gemcitabine and Abraxane, but patient response...
MIGRATION | MEDICINE, RESEARCH & EXPERIMENTAL | ACTIVATION | DUCTAL ADENOCARCINOMA | CELL INVASION | RHO-KINASE/ROCK | TUMOR | TENSION | EXTRACELLULAR-MATRIX | CLEAVAGE FURROW | REVEALS | CELL BIOLOGY | Liver - pathology | Humans | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - analogs & derivatives | Extracellular Matrix - metabolism | Deoxycytidine - pharmacology | Antineoplastic Agents - therapeutic use | rho-Associated Kinases - antagonists & inhibitors | CDC2 Protein Kinase - metabolism | Pancreatic Neoplasms - drug therapy | Deoxycytidine - therapeutic use | Neoplasm Metastasis | rho-Associated Kinases - metabolism | Actin Cytoskeleton - drug effects | src-Family Kinases - metabolism | Albumin-Bound Paclitaxel - therapeutic use | Antineoplastic Agents - pharmacology | Actin Cytoskeleton - metabolism | Neoplasm Invasiveness | Pancreatic Neoplasms - pathology | Albumin-Bound Paclitaxel - pharmacology | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - therapeutic use | Treatment Outcome | Disease Progression | Collagen - metabolism | Animals | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - pharmacology | Biosensing Techniques | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Deoxycytidine - analogs & derivatives
MIGRATION | MEDICINE, RESEARCH & EXPERIMENTAL | ACTIVATION | DUCTAL ADENOCARCINOMA | CELL INVASION | RHO-KINASE/ROCK | TUMOR | TENSION | EXTRACELLULAR-MATRIX | CLEAVAGE FURROW | REVEALS | CELL BIOLOGY | Liver - pathology | Humans | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - analogs & derivatives | Extracellular Matrix - metabolism | Deoxycytidine - pharmacology | Antineoplastic Agents - therapeutic use | rho-Associated Kinases - antagonists & inhibitors | CDC2 Protein Kinase - metabolism | Pancreatic Neoplasms - drug therapy | Deoxycytidine - therapeutic use | Neoplasm Metastasis | rho-Associated Kinases - metabolism | Actin Cytoskeleton - drug effects | src-Family Kinases - metabolism | Albumin-Bound Paclitaxel - therapeutic use | Antineoplastic Agents - pharmacology | Actin Cytoskeleton - metabolism | Neoplasm Invasiveness | Pancreatic Neoplasms - pathology | Albumin-Bound Paclitaxel - pharmacology | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - therapeutic use | Treatment Outcome | Disease Progression | Collagen - metabolism | Animals | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - pharmacology | Biosensing Techniques | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Deoxycytidine - analogs & derivatives
Journal Article